Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day.

Matthew H TaylorSophie LeboulleuxYury PanaseykinBhavana KondaChristelle De La FouchardièreBrett G M HughesAndrew G GianoukakisYoung Joo ParkIlia RomanovMonika K KrzyzanowskaDiana GarbinskyBintu SherifJie Janice PanTerri A BinderNicholas SauterRan XieMarcia S Brose

Published in: Cancer medicine (2022)

NCT02702388.

Keyphrases

double blind
placebo controlled
clinical trial
phase iii
papillary thyroid
phase ii
study protocol
open label
squamous cell
randomized controlled trial
lymph node metastasis
squamous cell carcinoma
cross sectional
young adults